Search Results 2751-2760 of 34410 for oral

  1. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

    retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids) - Patients with history Guillain-Barre syndrome or myasthenia gravis ...

  2. Durvalumab (intravenous route) - Side effects & uses - Mayo Clinic

    This medicine is also used alone to treat limited-stage small cell lung cancer (LS-SCLC) that cannot be removed by surgery in patients who have received other ...

  3. mammogram guidelines Archives - Mayo Clinic News Network

    ... Oral Health. THIS WEEK'S TOP STORIES Oral health: A window to your overall health Did you know that problems in your mouth can affect the rest of your body ...

  4. Obstructive sleep apnea - Doctors and departments - Mayo Clinic

    Departments that treat this condition. Dental Specialties · Neurology · Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric ...

  5. A First in Man Trial for Patients With Cancer - Mayo Clinic

    Inability to swallow oral meds or gastrointestinal disorder that might interfere with absorption of oral drugs; Major surgery within 28 days of first receipt ...

  6. Leukoplakia - Doctors and departments - Mayo Clinic

    ... Oral ulcerative condition, Facial volume loss. Show more areas of focus for Alison J. Bruce, M.B., Ch.B. By Mayo Clinic Staff · Request an appointment.

  7. A Study to Evaluate ORIN1001 in Idiopathic Pulmonary Fibrosis Subjects - Mayo Clinic

    not considered active). 9. Gastrointestinal disease (e.g., active bleeding or ulcers) or procedure that could interfere with oral absorption or tolerance of the ...

  8. Head and neck cancers - Doctors and departments - Mayo Clinic

    Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Pediatric Otolaryngology · Pediatrics · Physical ...

  9. Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease - Mayo Clinic

    Oral 5-aminosalicylate (5-ASA) compounds provided the dose prescribed has been stable for at least 4 weeks prior to randomization; dose must remain stable ...

  10. Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis - Mayo Clinic

    Treatment with >1 IV dose of cyclophosphamide and/or >14 days of oral cyclophosphamide and/or >14 days of prednisone/prednisolone (>30 mg/day) and/or >1 ...